Merck's hepatitis C drug boceprevir gains FDA panel's support

04/27/2011 | Wall Street Journal, The

An FDA panel of outside experts unanimously endorsed the approval of Merck & Co.'s boceprevir, saying the drug candidate marks an advance in the treatment of hepatitis C. The panel affirmed clinical data showing the efficacy of boceprevir in combination with standard medicines ribavirin and pegylated interferon. Merck proposed to commercialize it as Victrelis.

View Full Article in:

Wall Street Journal, The

Published in Brief:

SmartBrief Job Listings for Health Care

Job Title Company Location
Senior Director, Research
America's Health Insurance Plans (AHIP)
Washington, DC
Stop Loss Sales Executive
Blue Cross Blue Shield of MA
Boston, MA
Regional Director, Southeastern Region - State Affairs
America's Health Insurance Plans (AHIP)
Washington, DC
Field Representative-Oklahoma and Kansas
National Rural Electric Cooperative Association (NRECA)
Multiple Locations, SL_Multiple Locations
Market Intelligence Manager
Olympus Corporation of the Americas
Southborough, MA